Bart Classen

Shares of MannKind Corp. (NASDAQ: MNKD) fall as much as 27.105% prior to Tuesday's Endocrinologic and Metabolic Drugs Advisory Committee Meeting. Piper Jaffray analyst Joshua Schimmer noted that MannKind faces a "number of obstacles" in the U.S. Food and Drug Administration's (FDA) review of...

Shares of MannKind (NASDAQ: MNKD) are down approximately 2 percent amid comments from Summer Street analyst Bart Classen. Classen reported in an interview that MannKind's briefing documents may be “problematic” regarding Affinity 1 studies on the Afrezza Dreamboat insulin inhaler. The analyst...